Purlytin

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2004
01219982004

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2004
Review
2004
  • Drugs in R&D
  • 2004
The photosensitiser rostaporfin [Purlytin trade mark, SnET2, tin ethyl etiopurpurin, Sn(IV) etiopurpurin, PhotoPoint SnET2] was… (More)
Is this relevant?
Review
2002
Review
2002
PURPOSE To review the biophysical basis and current state of therapy for photodynamic closure of subfoveal choroidal… (More)
Is this relevant?
Review
2002
Review
2002
Pharmacia Corp, under license from Miravant Medical Technologies (formerly PDT Inc), is developing rostaporfin (SnET2, Purlytin… (More)
Is this relevant?
1998
1998
BACKGROUND Chest wall recurrence of breast cancer after mastectomy, radiation therapy, and chemotherapy poses a therapeutic… (More)
Is this relevant?
1998
1998
BACKGROUND AND OBJECTIVES Photodynamic therapy (PDT) using a photoreactive purpurin, tin ethyl etiopurpurin (SnET2, Purlytin… (More)
Is this relevant?